The size of the Global Cardiovascular Therapeutic Drugs Market is currently worth USD 135.4 billion in 2020. It is projected to reach USD 151.1 billion by 2025, growing at a CAGR of 2.22% during the forecast period.
According to WHO the cardiovascular diseases are the number one reason for the cause of death globally. Cardiovascular drugs help treat various diseases related to heart and blood vessels like arrhythmias and others. The rise in cases of cardiovascular diseases is the primary source of contribution to market growth. The prevalence of unhealthy lifestyles between people like change in food habits and drinking and smoking has increased the risk of cardiovascular diseases and increased CVD therapeutic drug usage.
For the treatment of these diseases, manufacturers are investing a lot of money in developing efficient and low-cost drugs, thus boosting the market.
The major restraint challenge for this market is to ensure that these drugs are accessible to all people suffering from cardiovascular problems. These drugs are expensive and poor people cannot afford these magazines. Countries that do not have proper healthcare facilities cannot provide these types of drugs to their people. The initiatives, when taken by the government, can solve these problems.
COVID-19 impact on the Cardiovascular Therapeutic Drugs Market
COVID 19 affects most to the people suffering from cardiovascular problems. The statistics, according to WHO, says that the mortality rate of people suffering from cardiovascular diseases and the Coronavirus at the same time is very high. This situation is an advantage for the cardiovascular therapist's drug makers. The patients in major countries are now using these drugs to rectify their diseases, which has led to the massive sale of these drugs. The rising government initiatives about making people aware of patients' problems suffering from CVD and corona have also contributed significantly to market growth. More research and development funds are being allocated now by manufacturers to develop drugs to cater to the vast number of patients. Thus, the growth of this market is expected to be positive in the future.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type, Production Technologies, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Bayer HealthCare AG, Bioniche Animal Halth Canada, Sanofi Animal Health, Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health, Inc., Merck & Co. Inc. and Protein Sciences |
This research report on the Global Cardiovascular Therapeutic Drugs Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.
Cardiovascular Therapeutic Drugs Market - By Disease Type:
Arteriosclerosis is the disease in which the arteries carrying oxygen and nutrients from the heart to the body become thick and stiff. It is a common problem, and with the rise in population, this disease will increase and, thus, the drug market.
Cardiac Arrhythmias therapeutic drug is expected to grow at the fastest rate among all others. The heart's beating frequency gets irregular in this disease, making it sometimes fast and sometimes slow. The prevalence of unhealthy lifestyle like junk food and smoking cause this disease. Manufacturers invest a lot of money to create drugs that can cure this disease, thus boosting the market growth.
Acute coronary syndrome therapeutic drugs are expected to provide significant growth to the overall market. It is a condition used to describe the situation when blood flow suddenly decreases and stops. The rise in the geriatric population and other factors is responsible for developing this disease and its therapeutic drug.
Hypertension or high blood pressure has the largest market share among all other sub-segments and is expected to grow at a reasonable rate in the future. The rise in unhealthy food habits and another unhealthy lifestyle have significantly contributed to the growth of this disease. The untapped market has motivated other manufacturers to enter this segment and cater to the rise in patients' numbers.
Cardiovascular Therapeutic Drugs Market - By Drug Class:
The combination drug class led the market in 2019 over the other and is expected to register significant growth in the future. Most people are suffering from various cardiovascular problems at the same time and thus require a combination of drugs to treat them. It has led to significant growth in revenue and is expected to do the same in the future.
Monotherapy means using the same type of drug to treat the patient. The patients now are getting diagnosed with multiple cardiovascular problems, and thus the market share of monotherapy drugs is getting decreased. However, the companies are now investing more in the research of drugs that can be singularly used to treat various diseases.
Cardiovascular Therapeutic Drugs Market - By Region:
Geographically, North America is expected to lead the market in terms of revenue and be expected to register profitable growth. Rising cases of cardiovascular diseases, along with improvement in healthcare facilities, will help in driving the market growth. The presence of major global drug makers will further support this growth through exports of medicines.
Europe had the second largest market share among all other regions. The rise in the old age population and focus shifting to improve the quality of healthcare facilities will help in the growth of the market.
The Asia Pacific is expected to grow at the fastest rate among all the regions and had the third-largest share in 2019. The rising population in countries like India and China and the prevalence of unhealthy habits are expected to contribute to the global cardiovascular therapeutic drugs market growth. Rising government initiatives to improve healthcare facilities will further propel the market.
TOP COMPANIES IN THE MARKET
Companies leading the global cardiovascular therapeutic drugs market profiled in the report are AstraZeneca, Novartis, Bristol-Myers Squibb (BMS), Pfizer, Sanofi, Merck, Bayer, Takeda, Boehringer Ingelheim, and Johnson & Johnson.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease
5.1.1 Arteriosclerosis
5.1.2 Cardiac arrhythmias
5.1.3 Myocardial infarction
5.1.4 Acute Coronary Syndrome
5.1.5 Peripheral artery disease
5.1.6 Coronary artery disease
5.1.7 Hypertension
5.1.8 Hyperlipidaemia
5.1.9 Thrombosis
5.1.10 Cardiac failure diseases
5.1.11 Others
5.2 By Drug Class
5.2.1 Monotherapies
5.2.2 Combination Therapies
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AstraZeneca
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Novartis
9.3 Bristol-Myers Squibb
9.4 Pfizer
9.5 Sanofi
9.6 Merck
9.7 Bayer
9.8 Takeda
9.9 Boehringer Ingelheim
9.10 Johnson & Johnson
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
